# Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-safety-and-biomarker-analysis-of-ensartinib-in-crizotinib-resistant-alk/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yunpeng Yang,Jianya Zhou,Jianying Zhou,Jifeng Feng,Wu Zhuang,Jianhua Chen,Jun Zhao,Wei Zhong,Yanqiu Zhao,Yiping Zhang,Yong Song,Yi Hu,Zhuang Yu,Youling Gong,Yuan Chen,Feng Ye,Shucai Zhang,Lejie Cao,Yun Fan,Gang Wu,Yubiao Guo,Chengzhi Zhou,Kewei Ma,Jian Fang,Weineng Feng,Yunpeng Liu,Zhendong Zheng,Gaofeng Li,Ning Wu,Wei Song,Xiaoqing Liu,Shijun Zhao,Lieming Ding,Li Mao,Giovanni Selvaggi,Xiaobin Yuan,Yuanqing Fu,Tao Wang,Shanshan Xiao,Li Zhang |
| Citations | 139 |
| DOI | 10.1016/s2213-2600(19)30252-8 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2980903799 |
| PMID | 31628085 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Weineng Feng](https://scholariq.org/researchers/weineng-feng/)

## Paper journal

- [The Lancet Respiratory Medicine](https://scholariq.org/journals/the-lancet-respiratory-medicine/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.